The I-HIT-MED registry records patients with rare brain or spinal cord tumours.
The University Medical Center Hamburg-Eppendorf in Germany is responsible for the international registry. In Switzerland, the Swiss Pediatric Oncology Group (SPOG) is responsible for managing the registry.
Background
The I-HIT-MED registry records patients with rare brain or spinal cord tumours. These are medulloblastomas, ependymal and pineal region tumours, as well as other rare tumours. In Switzerland, approximately 15 to 20 children and adolescents are expected to participate in this international registry study each year.
Why is the I-HIT-MED research project necessary?
The research project aims to improve future treatment for patients with rare brain and spinal cord tumours. To achieve this, researchers monitor the therapies used, investigate the tumour biology, and document the late effects.
At the same time, participating children and adolescents benefit from having their diagnosis verified by an independent reference center, which also advises the treatment team regarding therapy. This additional quality control can be beneficial for the participants.
In short
-
The researchers are using the registry to analyse the therapies, late effects and biology of certain brain and spinal cord tumours in children and adolescents.
-
The research project aims to improve future treatments for children and adolescents with rare brain and spinal cord tumours.
-
An international reference center ensures the diagnosis of the participating children and adolescents and provides therapeutic advice to the treating physicians. This additional quality assurance is beneficial for the young patients.
